BC World Pharmaceutical (200780) has 2 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩40M ($28K) in reported transaction value. The earliest filing StockDrifts holds for BC World Pharmaceutical is dated 2024-12-20; the most recent is 2026-03-31. Across these filings the average return since disclosure is +34.55%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | SELL | 임원퇴임 | 이승철 Seungcheol Lee | standing advisor | -60.4K | ₩4,545 | -1.1% | ₩274M ($191K) |
| 2026-03-26 | BUY | 주식배당 | 이승철 Seungcheol Lee | standing advisor | 5.5K | ₩4,865 | -0.9% | ₩27M ($19K) |
| 2026-03-26 | BUY | 주식배당 | 장태억 Jang Tae-eok | vice president | 1.5K | ₩4,865 | -0.9% | ₩7M ($5K) |
| 2026-03-26 | BUY | 주식배당 | 홍영기 Youngki Hong | vice president | 121.7K | ₩4,865 | -0.9% | ₩592M ($411K) |
| 2026-03-26 | BUY | 주식배당 | 홍성한 Hong Seong-han | CEO | 196.2K | ₩4,865 | -0.9% | ₩955M ($663K) |
| 2025-12-08 | BUY | 수증 | 홍영기 Youngki Hong | vice president | 1.0M | ₩4,249 | +27.1% | ₩4.2B ($3.0M) |
| 2025-12-08 | SELL | 증여 | 홍성한 Hong Seong-han | CEO | -1.4M | ₩4,249 | -27.1% | ₩5.7B ($4.0M) |
| 2025-03-28 | BUY | 주식배당 | 장태억 Jang Tae-eok | vice president | 1.4K | ₩3,984 | +35.5% | ₩5M ($4K) |
| 2025-03-28 | BUY | 주식배당 | 홍성한 Hong Seong-han | CEO | 301.1K | ₩3,984 | +35.5% | ₩1.2B ($833K) |
| 2025-03-28 | BUY | 주식배당 | 홍영기 Youngki Hong | vice president | 19.7K | ₩3,984 | +35.5% | ₩79M ($55K) |
| 2025-03-28 | BUY | 주식배당 | 이승철 Seungcheol Lee | standing advisor | 5.0K | ₩3,984 | +35.5% | ₩20M ($14K) |
| 2024-12-23 | BUY | Market Buy | 홍영기 Youngki Hong | Managing Director | 5.1K | ₩4,024 | +34.2% | ₩20M ($14K) |
| 2024-12-20 | BUY | Market Buy | 홍영기 Youngki Hong | Managing Director | 4.9K | ₩4,003 | +34.9% | ₩20M ($14K) |
Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.